Otokozawa Seiko, Ai Masumi, Van Himbergen Thomas, Asztalos Bela F, Tanaka Akira, Stein Evan A, Jones Peter H, Schaefer Ernst J
Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, Boston, MA 02111, USA.
Atherosclerosis. 2009 Jul;205(1):197-201. doi: 10.1016/j.atherosclerosis.2008.11.001. Epub 2008 Nov 12.
Atorvastatin and rosuvastatin at maximal doses are both highly effective in lowering low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. Rosuvastatin has been shown to be more effective than atorvastatin in lowering LDL-C, small dense LDL-C and in raising high-density lipoprotein (HDL) and its subclasses. Intestinal lipoproteins containing apolipoprotein (apo) B-48 are also thought to be atherogenic particles. Our purpose in this study was to compare the effects of daily oral doses of atorvastatin 80 mg/day and rosuvastatin 40 mg/day over a 6-week period on serum apo B-48 (a marker of intestinal lipoproteins) and remnant lipoprotein cholesterol (RemL-C) levels (a marker of partially metabolized lipoproteins of both intestinal and liver origin), using novel direct assays in 270 hyperlipidemic men and women. Both atorvastatin and rosuvastatin caused significant (p<0.0001) and similar median decreases in TG (-33.0%, -27.6%), RemL-C (-58.7%, -61.5%), and apoB-48 (-37.5%, -32.1%) as compared to baseline. Our findings utilizing a specific immunoassay and a fairly large number of subjects extend prior studies indicating that statins significantly lower apolipoprotein B containing lipoproteins of both intestinal and liver origin.
阿托伐他汀和瑞舒伐他汀的最大剂量在降低低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG）水平方面均非常有效。已证明瑞舒伐他汀在降低LDL-C、小而密LDL-C以及升高高密度脂蛋白（HDL）及其亚类方面比阿托伐他汀更有效。含有载脂蛋白（apo）B-48的肠道脂蛋白也被认为是致动脉粥样硬化颗粒。本研究的目的是，在270名高脂血症男性和女性中，使用新型直接检测方法，比较为期6周的每日口服80mg/天阿托伐他汀和40mg/天瑞舒伐他汀对血清apo B-48（肠道脂蛋白的标志物）和残余脂蛋白胆固醇（RemL-C）水平（肠道和肝脏来源的部分代谢脂蛋白的标志物）的影响。与基线相比，阿托伐他汀和瑞舒伐他汀均使TG（-33.0%，-27.6%）、RemL-C（-58.7%，-61.5%）和apoB-48（-37.5%，-32.1%）出现显著（p<0.0001）且相似的中位数下降。我们利用特异性免疫测定法和相当数量受试者的研究结果扩展了先前的研究，表明他汀类药物可显著降低肠道和肝脏来源的含载脂蛋白B的脂蛋白水平。
